Pharmacological Management of New-Onset Bipolar Disorder

 This is a case vignette created to exemplify a complex clinical problem and does not refer to any specific patient.This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid disorders, recommendations are likely to be “off label” from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. The responses from the expert clinicians are not meant to be practice guidelines but rather examples of thought processes that may go into pharmacotherapy decision making.Disclosure: Dr. Kratochvil has received grant support from, is a consultant to and/or member of the speaker's bureau of AstraZeneca, Cephalon, Eli Lilly and Company, GlaxoSmithKline, Forest, Novartis, McNeil, Organon, and Pfizer. Dr. DelBello has received industry research funding and has consulting relationships and/or is on the speaker's bureaus of Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Ortho-McNeil, and Pfizer. Dr. Upadhyaya is on an advisory board for Janssen and Shire, a consultant to Eli Lilly, and a member of the speaker's bureau for Abbott and has received research support from Eli Lilly and GlaxoSmithKline. Dr. Wozniak is a member of the speaker's bureau of and has received research funding from Eli Lilly, is a member of the speaker's bureau of Janssen and a consultant to Shire and Pfizer.

PII: S0890-8567(09)62224-3

doi: 10.1097/01.chi.0000177057.49278.7b

© 2005 The American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.